Schering's new X-ray imaging agent suspended
This article was originally published in Clinica
Executive Summary
Schering has temporarily suspended the sale of its X-ray contrast agent, Isovist 280, because of unexpected, delayed allergic skin reactions experienced by users mainly in Japan. Isovist 280 has been introduced in Japan, Germany and Austria since the end of 1994 and the US submission to the FDA had been planned for spring 1996. The latter will be delayed at least a year or two until new clinical trials are completed.